Abstract:In order to discover and develop the new HIV-1 Centrist, a series of 5-alkyl-6-(benzo[d][1,3]dioxol-5-ylalkyl)-2-mercaptopyrimidin-4(3H)-ones was synthesized and screened for their in vitro cytotoxicity against HIV-1. Most of the compounds we synthetized showed high activity against wild-type HIV-1 strain (IIIB) while IC50 values are in the range of 0.06-12.95μM. Among them, the most active HIV-1 inhibitor was compound 6-(benzo[d][1,3]dioxol-5-ylmethyl)-5-ethyl-2-((2-(4-hydroxyphenyl)-2-oxoethyl)thio)pyrimidin-4(3H)-one (5b), which exhibited similar HIV-1 inhibitory potency (IC50 = 0.06μM, CC50 = 96.23μM) compared with nevirapine (IC50 = 0.04μM, CC50 >200μM) and most of compounds exhibited submicromolar IC50 values indicating they were specific RT inhibitors. The compounds 5b, 6-(benzo[d] [1,3]dioxol-5-yl)-5-ethyl-2-((2-(4-hydroxyphenyl)-2-oxoethyl)thio)pyrimidin-4(3H)-one (5c) and 4-(2-((4-(benzo[d][1,3]dioxol-5-ylmethyl)-5-ethyl-6-oxo-1,6-dihydro pyrimidin-2-yl)thio)acetyl)phenylbenzo[d][1,3]dioxole-5-carboxylate (5r) were selected for further study. It was found that all of them had little toxicity to peripheral blood mononuclear cell (PBMC), and had a good inhibitory effect on the replication of HIV-1 protease inhibitor resistant strains, fusion inhibitor resistant strains and nucleosides reverse transcriptase inhibitor resistant strains, as well as on clinical isolates. Besides, compound 5b and 5c showed inhibition of HIV-1 RT RNA-dependent DNA polymerization activity and DNA-dependent DNA polymerization activity, while compound 5r only showed inhibition of HIV DNA-dependent DNA polymerization activity, which was different from classical reverse transcriptase inhibitors. Our study which offered the preliminary structure-activity relationships and modeling studies of these new compounds has provided the valuable avenues for future molecular optimization.

Development and Preclinical Studies of Broad-Spectrum Anti-Hiv Agent (3'R,4'r)-3-cyanomethyl-4-methyl-3',4'-di-o-(s)-camphanoyl-(+)-cis-khellactone (3-Cyanomethyl-4-methyl-dck).

Anti-AIDS Agents 82: Synthesis of Seco-(3′R,4′r)-3′,4′-di-o-(s)-camphanoyl-(+)-cis-khellactone (DCK) Derivatives As Novel Anti-Hiv Agents

Anti-Aids Agents 84. Synthesis and Anti-Human Immunodeficiency Virus (hiv) Activity of 2 '-Monomethyl-4-methyl- and 1 '-Thia-4-methyl-(3 ' R,4 ' R)-3 ',4 '-Di-o-(s)-camphanoyl-(+)-cis-khellactone (dck) Analogs

Anti-AIDS Agents. Part 62: Anti-HIV Activity of 2′-Substituted 4-Methyl-3′,4′-di-o-(−)-camphanoyl-(+)-cis-khellactone (4-Methyl DCK) Analogs

Anti-AIDS Agents 87. New Bio-Isosteric Dicamphanoyl-Dihydropyranochromone (DCP) and Dicamphanoyl-Khellactone (DCK) Analogues with Potent Anti-Hiv Activity

Structure-Based Discovery and Characterization of a Preclinical Drug Candidate for the Treatment of HIV-1 Infection

Structure-Based Discovery of Novel NH2-Biphenyl-Diarylpyrimidines As Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: from NH2-Naphthyl-Diarylpyrimidine to NH2-Biphenyl-Diarylpyrimidine.

Anti-AIDS agents. Part 56: Synthesis and anti-HIV activity of 7-thia-di-O-(−)-camphanoyl-(+)-cis-khellactone (7-thia-DCK) analogs

Anti-AIDS Agents 86. Synthesis and Anti-Hiv Evaluation of 2′,3′-Seco-3′-nor DCP and DCK Analogues

A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.

Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies

Design,synthesis and activity evaluation of new anti-HIV-1 CXCR4 inhibitors

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.

Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2- d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation

Synthesis and Biological Evaluation of Dihydroquinazoline-2-amines As Potent Non-Nucleoside Reverse Transcriptase Inhibitors of Wild-Type and Mutant HIV-1 Strains.

Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation

Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

Optimization of the Antiviral Potency and Lipophilicity of Halogenated 2,6‐diarylpyridinamines As a Novel Class of HIV‐1 NNRTIS

Design, synthesis and anti-HIV evaluation of 5-alkyl- 6-(benzo[d][1,3]dioxol-5-alkyl)-2-mercaptopyrimidin-4(3H)-ones as potent HIV-1 NNRTIs

Anti-Aids Agents 72. Bioisosteres (7-Carbon-dcks) of the Potent Anti-Hiv Lead Dck